Although THC and CBD get the most attention from medical marijuana researchers, other elements, such as cannflavins, may play a role in reducing pain as well. Because of how they reduce inflammation, Cannflavins might become another way to relieve chronic pain, rather than using opioids. Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are two of the more abundant active molecules in cannabis by volume and are the predominant molecules that receive attention when clinicians discuss the therapeutic role of medicinal cannabis.
Known for its psychoactive properties, THC can help treat chronic pain, but it has also been linked to psychosis with frequent and heavy use. CBD, meanwhile, is the active ingredient in Epidiolex, the first FDA-approved cannabis-based medicine for childhood seizure disorders. Other parts of the cannabis plant, however, are now being studied and found effective.
In the Phytochemistry journal’s August issue, researchers at the University of Guelph will be publishing how the Cannabis sativa L plant produces two molecules, cannflavin A and cannflavin B, which are 30 times more effective than aspirin by weight at reducing inflammation in cell models.
Cannflavins may become alternatives for relief of acute and chronic pain and provide a pathway other than opioids. They are distinct from THC and CBD cannabinoids, and act as potent inhibitors of prostaglandin (PG) E2 production in cultured rheumatoid synovial cells.
Cannflavins are non-psychoactive and target the inflammation at the source, making them ideal painkillers.